New real-world data on Elocta compared with standard half-life factor VIII

Positive results from the A-SURE study were presented at the 30th International Society on Thrombosis and Hemostasis (ISTH) Congress in London, demonstrating improved prophylactic effectiveness in Elocta (efmoroctocog alfa) treated patients compared to a matched treatment group on SHL FVIII treatments, according to Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi.

Elocta was launched in Europe in January 2016 and at the time was the first hemophilia treatment in the European Union to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days. Elocta generated revenues of 4,585 billion Swedish kronor ($458 million) in 2021, up 2% year-on-year, for Sobi.

A-SURE was a 24-month prospective, non-interventional, European multicenter study including more than 350 participants in 45 centers and the largest directly comparative study in people with hemophilia A (PwHA). The results were presented orally by Professor Johannes Oldenburg, the study principal investigator.